18F-FDG small-animal PET/CT differentiates trastuzumab- responsive from unresponsive human breast cancer xenografts in athymic mice

Journal of Nuclear Medicine

Volumn 50, Issue 11, 2009, Pages 1848-1856

  McLarty, Kristin ^a   Fasih, Aisha ^a   Scollard, Deborah A ^a   Done, Susan J ^b,c   Vines, Douglass C ^b,c   Green, David E ^c   Costantini, Danny L ^a   Reilly, Raymond M ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

18F FDG; HER2; PET; Trastuzumab; Tumor response

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PENTETATE INDIUM IN 111; PHOSPHATE BUFFERED SALINE; TRASTUZUMAB; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CALCULATION; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GLUCOSE UTILIZATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INJECTION; MONITORING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTO ONCOGENE; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70350714454     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.067231     Document Type: Article

References (37)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science. 1987;235:177-182.
2. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-3685. (Pubitemid 46252462)
3. Plosker G, Keam S. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs. 2006;66:449-475. (Pubitemid 44050433)
4. Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
5. Vogel C. Trastuzumab monotherapy. Breast Cancer Res Treat. 2003;81(suppl 1):S67-S68.
6. Popat S, Smith IE. Therapy insight: anthracyclines and trastuzumab - the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol. 2008;5:324-335. (Pubitemid 351780949)
7. Charatan F. News feature: costly US anticancer drugs pose problems for doctors and patients. BMJ. 2008;337:a778.
8. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693. (Pubitemid 37328919)
9. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol. 2005;23:1664-1673. (Pubitemid 46211421)
10. Wu D, Gambhir SS. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives. Clin Breast Cancer. 2003;4(suppl 1):S55-S63. (Pubitemid 36621617)
11. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med. 1996; 37:931-938. (Pubitemid 126447124)
12. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806-1814. (Pubitemid 39663314)
13. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695.
14. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676-1688.
15. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111. (Pubitemid 23332245)
16. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144-1150. (Pubitemid 43741076)
17. 18F]- fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer. 2000;1:156-161.
18. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803. (Pubitemid 32538187)
19. Kawada K, Murakami K, Sato T, et al. Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol. 2007;37:44-48. (Pubitemid 47090722)
20. Asakura H, Takashima H, Mitani M, et al. Unknown primary carcinoma, diagnosed as inflammatory breast cancer, and successfully treated with trastuzumab and vinorelbine. Int J Clin Oncol. 2005;10:285-288. (Pubitemid 41242186)
21. Sugie T, Nagai T, Ohgaki K. A case of HER2-positive metastatic breast cancer responding to trastuzumab plus gemcitabine combination therapy [in Japanese]. Gan To Kagaku Ryoho. 2008;35:683-686.
22. 111In-DTP A pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med. 2009;50:1340-1348.
23. 18F-FDG PET studies in mice. J Nucl Med. 2006;47:999-1006.
24. 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging. 2009;36:81-93.
25. National Institutes of Health (NIH), Public Health Service. Guide for the Care and Use of Laboratory Animals. NIH publication no. 86-123 Bethesda, MD: NIH; 1985.
26. Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915-1924. (Pubitemid 350212117)
27. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS. How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging. 2006;33(suppl 1):16-21.
28. 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med. 2007;48:602-607.
29. 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med. 2005;46:1531-1536.
30. Shah C, Miller TW, Wyatt SK, et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res. 2009;15:4712-4721.
31. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16.
32. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317-1323. (Pubitemid 44392212)
33. 18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166-170.
34. Ikenaga N, Otomo N, Toyofuku A, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 2007;73:1151-1157.
35. 18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250-258.
36. 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48:1266-1272.
37. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347.